Dupilumab (Atopic Dermatitis)
Dupilumab — Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderate-to-severe atopic dermatitis | Adults and children ≥6 months | Monotherapy or with TCS; when topical Rx inadequate | FDA Approved (2017 adults; 2019 ≥12y; 2020 ≥6y; 2022 ≥6mo) |
| Moderate-to-severe asthma | Adults and children ≥6 years | Add-on maintenance; eosinophilic phenotype or OCS-dependent | FDA Approved |
| CRSwNP | Adults and children ≥12 years | Add-on maintenance | FDA Approved |
| Eosinophilic oesophagitis | Adults and children ≥1 year (≥15 kg) | Monotherapy | FDA Approved |
| Prurigo nodularis | Adults | Monotherapy | FDA Approved |
| COPD (eosinophilic) | Adults | Add-on maintenance | FDA Approved |
| Chronic spontaneous urticaria | Adults and children ≥12 years | For patients symptomatic despite H1 antihistamine | FDA Approved (Apr 2025) |
| Bullous pemphigoid | Adults | With tapering OCS | FDA Approved (Jun 2025) |
| Allergic fungal rhinosinusitis | Adults and children ≥6 years (post-surgery) | Monotherapy | FDA Approved (Feb 2026) |
Dupilumab (Dupixent) is the first biologic therapy approved for moderate-to-severe atopic dermatitis (March 2017). It is a fully human IgG4 monoclonal antibody that targets the interleukin-4 receptor alpha (IL-4Rα) subunit, blocking signalling of both IL-4 and IL-13 — two key drivers of type 2 inflammation. For AD, dupilumab is approved across all age groups from 6 months upward and can be used with or without topical corticosteroids. The AAD guidelines provide a strong recommendation for dupilumab in uncontrolled moderate-to-severe AD. It carries no boxed warning, differentiating it from JAK inhibitors (which carry 5-component boxed warnings) and topical calcineurin inhibitors (malignancy-related warning).
Dosing
Adult Dosing for Atopic Dermatitis
| Clinical Scenario | Loading Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate-to-severe AD — adults | 600 mg (2 × 300 mg SC) | 300 mg Q2W | 300 mg Q2W | Administer loading dose as two separate 300 mg injections at different sites on Day 1. Can use ± TCS TCIs may be used on problem areas (face, neck, intertriginous, genital areas) |
Paediatric Dosing for Atopic Dermatitis (≥6 Years)
| Body Weight | Loading Dose | Maintenance Dose | Frequency | Notes |
|---|---|---|---|---|
| ≥60 kg | 600 mg (2 × 300 mg) | 300 mg | Q2W | Same as adult dosing |
| 30 to <60 kg | 400 mg (2 × 200 mg) | 200 mg | Q2W | Uses 200 mg/1.14 mL presentation |
| 15 to <30 kg | 600 mg (2 × 300 mg) | 300 mg | Q4W | Less frequent dosing; higher loading dose relative to weight |
Paediatric Dosing for Atopic Dermatitis (6 Months to 5 Years)
| Body Weight | Loading Dose | Maintenance Dose | Frequency | Notes |
|---|---|---|---|---|
| 15 to <30 kg | None | 300 mg | Q4W | No loading dose in this age group. Must be administered by a caregiver |
| 5 to <15 kg | None | 200 mg | Q4W | No loading dose. Uses 200 mg/1.14 mL presentation. Must be administered by a caregiver |
Children aged 6 months to 5 years do NOT receive a loading dose (unlike children ≥6 years and adults). The Q4W frequency for lower-weight children (<30 kg in ≥6y group; all in 6mo–5y group) reflects the relatively higher exposure per kilogram in younger, smaller patients. Complete age-appropriate vaccinations prior to initiation (FDA PI). Administer by caregiver in children <12 years; under adult supervision in children ≥12 years.
Pharmacology
Mechanism of Action
Dupilumab is a fully human IgG4 monoclonal antibody that specifically binds the interleukin-4 receptor alpha (IL-4Rα) subunit, which is shared by both IL-4 and IL-13 receptor complexes. By blocking this shared subunit, dupilumab inhibits signalling of both IL-4 and IL-13 — two type 2 cytokines that play central roles in the pathogenesis of atopic dermatitis. IL-4 drives Th2 cell differentiation, IgE class switching, and barrier dysfunction, while IL-13 promotes skin inflammation, fibrosis, and pruritus through direct effects on keratinocytes and sensory neurons. Dupilumab reduces type 2 inflammatory biomarkers (total IgE, CCL17/TARC, CCL18, periostin) and improves epidermal barrier integrity by normalizing gene expression of structural proteins (filaggrin, loricrin, claudin-1). Unlike JAK inhibitors that broadly suppress multiple cytokine pathways, dupilumab selectively targets the type 2 axis while preserving Th1 and Th17 immune responses, contributing to its favourable infection profile.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC bioavailability ~64%; Tmax ~1 week (range 2–7 days); steady-state achieved by ~16 weeks with 300 mg Q2W after 600 mg loading dose; mean trough concentration at steady state ~73 mg/L | Loading dose accelerates attainment of therapeutic levels; weekly injection not needed. Predictable PK across body weight range |
| Distribution | Volume of distribution ~4.8 L (typical of IgG antibodies with predominantly intravascular distribution) | Limited tissue distribution; confined mainly to blood and extracellular fluid |
| Metabolism | Degraded by proteolytic catabolism into amino acids (like endogenous IgG); NOT metabolised by cytochrome P450 enzymes | No hepatic drug interactions. No dose adjustment for hepatic or renal impairment. CYP450 substrate levels (e.g., warfarin, statins) are not expected to be affected |
| Elimination | Apparent clearance ~0.34 L/day; elimination t½ ~2 weeks; target-mediated drug disposition (TMDD) at lower concentrations; washout ~10–13 weeks after last dose | Q2W dosing maintains trough above therapeutic threshold; longer washout period means effects persist weeks after discontinuation |
Side Effects
Adverse event data for dupilumab in AD are from four pivotal trials in adults (SOLO 1, SOLO 2, CHRONOS, and AD-1021), one in adolescents (AD-1526), one in children 6–11 years (AD-1652), and one in children 6 months to 5 years (AD-1539). Data below are from FDA PI Table 5 (February 2026 revision) for the 300 mg Q2W monotherapy and DUPIXENT + TCS groups through Week 16.
Adults — Monotherapy (SOLO 1, SOLO 2, AD-1021; Week 0–16)
| Adverse Reaction | Dupilumab 300 mg Q2W | Placebo | Clinical Note |
|---|---|---|---|
| Injection site reactions | 15% | 6% | Mostly mild/moderate; self-limiting; most common with the loading dose |
| Conjunctivitis (cluster) | 10% | 2% | Signature dupilumab AE in AD. Includes allergic, bacterial, viral conjunctivitis, eye irritation, and eye inflammation. Most cases mild/moderate; resolved during treatment |
| Oral herpes | 4% | 2% | Mild reactivation events; not typically requiring treatment discontinuation |
| Blepharitis | 2% | <1% | Eyelid inflammation; related to the conjunctivitis phenomenon |
| Eye pruritus | 2% | <1% | Part of the ocular AE cluster; advise patients to report new eye symptoms |
| Other herpes simplex virus infection | 2% | 1% | Includes herpes simplex (non-oral, non-eczema herpeticum) |
| Keratitis (cluster) | 1% | <1% | Includes ulcerative keratitis, allergic keratitis; consider ophthalmology referral |
| Dry eye | 1% | 0% | Part of the ocular AE spectrum |
Adults — With TCS (CHRONOS; Week 0–16)
| Adverse Reaction | Dupilumab + TCS | Placebo + TCS | Clinical Note |
|---|---|---|---|
| Conjunctivitis (cluster) | 16% | 9% | Higher rate than monotherapy; 52-week rate 17.9% vs 7.9% placebo + TCS |
| Injection site reactions | 10% | 6% | Comparable to monotherapy data |
| Oral herpes | 8% | 3% | Higher rate with concomitant TCS than monotherapy |
| Keratitis (cluster) | 4% | 0% | Higher than monotherapy; warrants ophthalmology assessment |
| Eye pruritus | 3% | <1% | Part of the ocular cluster |
| Other herpes simplex virus infection | 3% | 0% | Slightly higher with TCS combination |
| Blepharitis | 1% | <1% | Consistent with monotherapy |
| Dry eye | 1% | 0% | Consistent with monotherapy |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Hypersensitivity (anaphylaxis, AGEP, serum sickness, angioedema, erythema nodosum, erythema multiforme) | <1% | Variable (minutes to weeks) | Discontinue dupilumab immediately; institute appropriate therapy. Permanent contraindication if confirmed. |
| Eosinophilic conditions (eosinophilic pneumonia, EGPA/Churg-Strauss) | Rare | Variable; especially during OCS taper | Alert for vasculitic rash, worsening pulmonary symptoms, cardiac complications, neuropathy. Consider withholding dupilumab. |
| New-onset psoriasis | Post-marketing | Weeks to months after first dose | Dermatologic evaluation. Consider discontinuation; partial/complete resolution reported after stopping dupilumab. |
| Arthralgia / psoriatic arthritis | Post-marketing | Days to months after first dose | Report joint symptoms. Rheumatological evaluation if persistent. Some cases resolved while continuing treatment. |
Conjunctivitis is the most clinically significant dupilumab-associated adverse event in AD, occurring in up to 22% in the LIBERTY AD CAFÉ trial (dupilumab + TCS). It appears specific to the AD population (rates are not increased in asthma or CRSwNP trials). Most cases are mild-to-moderate and resolve during treatment. Advise patients to report new onset or worsening eye symptoms. Consider ophthalmological referral for cases that do not resolve with standard treatment (artificial tears, topical antihistamines) or for keratitis.
Drug Interactions
Dupilumab is a monoclonal antibody, not a small molecule. It is degraded by proteolysis (like endogenous IgG) and does not interact with cytochrome P450 enzymes. Therefore, CYP-mediated drug interactions are not expected. Population PK analysis confirmed that commonly co-administered medications had no effect on dupilumab pharmacokinetics.
Monitoring
-
Ocular Symptoms
Each visit
Routine Ask about new onset or worsening eye symptoms (redness, itching, discharge, blurred vision). Conjunctivitis occurred in 10–22% in AD trials. Refer to ophthalmology for persistent conjunctivitis or suspected keratitis. -
Disease Severity
16 weeks, then periodically
Routine Assess treatment response at 16 weeks (standard endpoint from pivotal trials). Use validated tools (IGA, EASI, NRS pruritus). Continued improvement may be seen beyond 16 weeks. -
Injection Site Reactions
First doses, then as needed
Trigger-Based Injection site reactions (15% in monotherapy) are mostly mild/moderate and self-limiting. Most common with loading dose. Rotate injection sites. -
Eosinophil Counts
If clinically indicated
Trigger-Based Transient eosinophilia may occur. Clinically significant eosinophilic conditions (eosinophilic pneumonia, EGPA) are rare but should be considered in patients with worsening pulmonary symptoms, especially during OCS taper. -
Helminth Infection Screen
Baseline (endemic areas)
Routine Treat pre-existing helminth infections before initiating dupilumab. If patients become infected during treatment and do not respond to anti-helminth treatment, discontinue dupilumab until infection resolves. -
Joint Symptoms
Each visit
Trigger-Based New-onset arthralgia and psoriatic arthritis reported post-marketing. Advise patients to report new or worsening joint symptoms. Rheumatological evaluation if persistent.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to dupilumab or any excipients in Dupixent (L-arginine, L-histidine, polysorbate 80, sodium acetate, sucrose, water for injection).
Relative Contraindications (Specialist Input Recommended)
- Pre-existing helminth infection — treat infection before initiating dupilumab. If infection develops during treatment and does not respond to anti-helminth therapy, discontinue dupilumab.
- Planned live vaccination — avoid live vaccines; complete all recommended vaccinations before initiating treatment.
Use with Caution
- Pregnancy — limited human data. IgG antibodies cross the placenta, particularly in the third trimester. Animal studies showed no embryo-foetal toxicity. Pregnancy exposure registry available (1-844-387-4936).
- Lactation — unknown whether dupilumab is excreted in human milk. IgG is present in breast milk. Weigh developmental and health benefits of breastfeeding against clinical need for dupilumab.
- Patients with co-morbid asthma — do not adjust or discontinue asthma medications without physician consultation. Dupilumab is NOT for acute bronchospasm or status asthmaticus.
- History of ocular disorders — patients with pre-existing conjunctivitis or keratitis may be at higher risk. Monitor closely.
Dupilumab carries no FDA boxed warning. This is a significant safety differentiation from JAK inhibitors (which carry 5-component boxed warnings for infections, mortality, malignancy, MACE, and thrombosis) and topical calcineurin inhibitors (which carry boxed warnings for malignancy risk). The absence of a boxed warning, combined with strong AAD guideline recommendation, supports dupilumab as the preferred first-line systemic therapy for moderate-to-severe AD in appropriate patients.
Patient Counselling
Purpose of Therapy
Dupixent is a biologic medicine given as an injection under the skin to treat moderate-to-severe eczema that is not controlled by skin creams alone. It works by blocking specific proteins (IL-4 and IL-13) that cause the inflammation and itch of eczema. It is not a steroid and does not suppress the immune system broadly. Most patients see significant improvement within 16 weeks.
How to Administer
Dupixent is injected under the skin (subcutaneously) into the thigh, abdomen (avoiding 5 cm around the navel), or the outer upper arm (if given by a caregiver). Rotate injection sites. Allow the pre-filled pen or syringe to reach room temperature before injecting (45 minutes for the 300 mg; 30 minutes for the 200 mg). Store refrigerated (2–8°C); can be kept at room temperature up to 25°C for 14 days maximum. Children under 12 must receive injections from a caregiver.
Sources
- DUPIXENT (dupilumab) injection, for subcutaneous use — FDA Full Prescribing Information (February 2026 revision). regeneron.com Current FDA label with all 9 approved indications, weight-based dosing tables, adverse event data across AD, asthma, CRSwNP, EoE, PN, COPD, CSU, BP, and AFRS trials.
- DUPIXENT (dupilumab) injection — FDA Prescribing Information (2024 revision). accessdata.fda.gov Detailed adverse event tables including paediatric AD data (6 months–5 years, AD-1539) and long-term safety extension data (AD-1434).
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa1610020 SOLO 1 and SOLO 2 pivotal monotherapy trials (N=1,379). IGA 0/1 at 16 weeks: 38% (SOLO 1) and 36% (SOLO 2) vs 10% and 8% placebo. Basis for 2017 FDA approval.
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/S0140-6736(17)31191-1 52-week trial demonstrating sustained efficacy and safety of dupilumab + TCS; IGA 0/1 at 52 weeks: 40% vs 12.5% placebo + TCS.
- Cork MJ, Thaqi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase 3 clinical trial (LIBERTY AD ADOL). Br J Dermatol. 2020;182(1):85–96. doi:10.1111/bjd.18476 Adolescent AD-1526 trial (N=251, 12–17 years) supporting 2019 paediatric expansion; safety consistent with adults.
- Paller AS, Siegfried EC, Thaqi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282–1293. doi:10.1016/j.jaad.2020.06.054 AD-1652 paediatric trial (N=367, 6–11 years) with weight-based dosing; IGA 0/1 at 16 weeks: 30–33% vs 12% placebo + TCS.
- Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi:10.1016/S0140-6736(22)01539-2 AD-1539 infant/toddler trial (N=161, 6 months–5 years) demonstrating efficacy and safety in the youngest AD population.
- Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical and systemic therapies. J Am Acad Dermatol. 2024;90(2):e65–e92. doi:10.1016/j.jaad.2023.08.102 Updated AAD guidelines providing strong recommendation for dupilumab as first-line systemic therapy in adults with moderate-to-severe AD.
- Dupilumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. ncbi.nlm.nih.gov/books/NBK585114 Comprehensive NCBI reference covering mechanism, administration, adverse effects, and contraindications for dupilumab across all indications.
- Thyssen JP, de Bruin-Weller MS, Paller AS, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459–473. doi:10.1111/bjd.17869 Comprehensive analysis of conjunctivitis across all dupilumab AD trials; established that conjunctivitis is AD-specific (not seen in asthma/CRSwNP trials) and mostly mild-to-moderate.
- Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Clin Transl Sci. 2020;13(5):1098–1107. doi:10.1111/cts.12832 Investigates mechanisms of dupilumab-associated conjunctivitis including OX40L-driven conjunctival inflammation specific to the AD population.
- Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20(3):443–456. doi:10.1007/s40257-019-00445-7 Pooled infection analysis demonstrating dupilumab does not increase overall infection risk; non-herpetic skin infections were lower with dupilumab than placebo.
- Langley RG, Gherardi G, Coleman A, et al. The safety data of dupilumab for the treatment of moderate-to-severe atopic dermatitis in infants, children, adolescents, and adults. Am J Clin Dermatol. 2025;26(6):981–1002. doi:10.1007/s40257-025-00918-w Most recent comprehensive safety analysis across all age groups; pooled data from pivotal trials and long-term extensions confirming consistent safety profile from infants to adults.